Charles W. Newton, Director at Keros Therapeutics, Inc. (KROS), sold 550 shares at $10.04 ($6K) on 2026-06-11, disclosed to the SEC on 2026-06-15.
Scheduled sale ($6k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| LYEL | SELL | 2025-08-13 | $3K | — | Filing → |
| LYEL | BUY | 2025-03-18 | $224K | — | Filing → |